Phase II study of temozolomide and thalidomide in patients with unresectable or metastatic leiomyosarcoma

Sarcoma

Volumn 2008, Issue , 2008, Pages

  Taub, Robert N ^d   Boyar, Michelle S ^a   Hesdorffer, Mary ^b   Keohan, Mary Louise ^a   Jin, Zhezhen ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Mesothelioma Applied Research Foundation   (United States)

^c Columbia University ^*  (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; THALIDOMIDE;

AGED; ANEMIA; ANOREXIA; ARTICLE; ATAXIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HUMAN; INFECTION; LEIOMYOSARCOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

EID: 57449100641     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2008/412503     Document Type: Article

References (20)

1. Jemal A., Murray T., Ward E., Cancer statistics, 2005 CA: A Cancer Journal for Clinicians 2005 55 1 10 30
2. Edmonson J. H., Ryan L. M., Blum R. H., Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas Journal of Clinical Oncology 1993 11 7 1269 1275
3. Antman K. H., Ryan L., Elias A., Sherman D., Grier H. E., Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma Journal of Clinical Oncology 1989 7 1 126 131
4. Gottlieb J. A., Benjamin R. S., Baker L. H., Role of DTIC (NSC- 84538) in the chemotherapy of sarcomas Cancer Treatment Reports 1976 60 2 199 203
5. Borden E. C., Amato D. A., Rosenbaum C., Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas Journal of Clinical Oncology 1987 5 6 840 850
6. Demetri G. D., von Mehren M., Blanke C. D., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors The New England Journal of Medicine 2002 347 7 472 480
7. Brennan M. F., Casper E. S., Harrison L. B., DeVita V. T. Jr., Hellman S., Rosenberg S. A., Soft tissue sarcoma Cancer Principles and Practice of Oncology 1997 5th Philadelphia, Pa, USA Lippincott-Raven 1738 1788
8. Tsang L. L. H., Quarterman C. P., Gescher A., Slack J. A., Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide Cancer Chemotherapy and Pharmacology 1991 27 5 342 346
9. Stevens M. F. G., Newlands E. S., From triazines and triazenes to temozolomide European Journal of Cancer Part A 1993 29 7 1045 1047
10. Bower M., Newlands E. S., Bleehen N. M., Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma Cancer Chemotherapy and Pharmacology 1997 40 6 484 488
11. Middleton M. R., Grob J. J., Aaronson N., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma Journal of Clinical Oncology 2000 18 1 158 166
12. Talbot S. M., Keohan M. L., Hesdorffer M., A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma Cancer 2003 98 9 1942 1946
13. Trent J. C., Beach J., Burgess M. A., A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas Cancer 2003 98 12 2693 2699
14. Woll P. J., Judson I., Lee S. M., Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group European Journal of Cancer 1999 35 3 410 412
15. Kumar S., Rajkumar S. V., Thalidomide and lenalidomide in the treatment of multiple myeloma European Journal of Cancer 2006 42 11 1612 1622
16. Hwu W.-J., Krown S. E., Menell J. H., Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma Journal of Clinical Oncology 2003 21 17 3351 3356
17. Kulke M. H., Stuart K., Enzinger P. C., Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors Journal of Clinical Oncology 2006 24 3 401 406
18. Garcia del Muro X., Lopez-Pousa A., Martin J., A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the spanish group for research on sarcomas Cancer 2005 104 8 1706 1712
19. Anderson S., Aghajanian C., Temozolomide in uterine leiomyosarcomas Gynecologic Oncology 2005 98 1 99 103
20. Hegi M. E., Diserens A.-C., Gorlia T., MGMT gene silencing and benefit from temozolomide in glioblastoma The New England Journal of Medicine 2005 352 10 997 1003